Research Article

Deoxyschizandrin Inhibits the Proliferation, Migration, and Invasion of Bladder Cancer Cells through ALOX5 Regulating PI3K-AKT Signaling Pathway

Baojin Chi,1 Yao Sun,2 Jintao Zhao,3 and Yugang Guo1

1Department of Urology, The First Affiliated Hospital of Jiamusi University, Heilongjiang 154007, China
2Department of Vascular Surgery, The First Affiliated Hospital of Jiamusi University, Heilongjiang 154007, China
3Department of Gastroenterology, The First Affiliated Hospital of Jiamusi University, Heilongjiang 154007, China

Correspondence should be addressed to Yugang Guo; guoyugangjms@sina.com

Received 29 March 2022; Revised 21 April 2022; Accepted 3 May 2022; Published 25 May 2022

Academic Editor: Fu Wang

Copyright © 2022 Baojin Chi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Deoxyschizandrin has a significant inhibitory effect on a variety of tumor cells. However, the effect of Deoxyschizandrin on bladder cancer cells and its mechanism are still unclear. Methods. Bladder cancer cells were treated with different concentrations of Deoxyschizandrin for 24 h, 48 h, and 72 h. The inhibition rate of cell proliferation was detected by CCK-8 assay. The changes of cell migration and invasion were detected by wound healing and Transwell assay. Based on the structure of Deoxyschizandrin, the protein targets of Deoxyschizandrin were predicted by bioinformatics database and verified by RNA and protein. Then, the expressions of ALOX5 and PI3K-AKT signaling pathway proteins were detected by Western blot in bladder cancer cells treated with Deoxyschizandrin. Result. Deoxyschizandrin inhibited the proliferation, migration, and invasion of bladder cancer cells in a time- and concentration-dependent manner. Bioinformatics analysis showed that Deoxyschizandrin had 100 protein targets; among them, the score of ALOX5 was the highest, and the mRNA and protein levels of ALOX5 decreased after treatment with different concentrations of Deoxyschizandrin. Western blot results showed that compared with the control group, Deoxyschizandrin could significantly reduce the expression of p-PI3K and p-AKT, and overexpression of ALOX5 could significantly enhance the expression of p-PI3K and p-AKT. Compared with Deoxyschizandrin or overexpression of ALOX5, the expression of p-PI3K and p-AKT of Deoxyschizandrin combined with overexpression of ALOX5 recovered. Conclusion. Deoxyschizandrin inhibits the proliferation, migration, and invasion of bladder cancer cells through ALOX5 regulating PI3K-AKT signaling pathway.

1. Introduction

Bladder cancer has been a common malignant tumor worldwide. The International Cancer Research Center shows that the number of new cases of bladder cancer in 2020 is about 573,278 and the number of deaths is about 212,536 in the world. The incidence rate of bladder cancer is sixth in male malignant tumors and ninth in mortality [1]. Bladder cancer can be divided into nonmuscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). Nonmuscle invasive bladder cancer accounts for 75% of bladder cancer [2]. Therefore, it is particularly important to explore the molecular mechanism of the invasion and metastasis of the bladder cancer and to study the drugs that inhibit the metastasis ability of the bladder cancer. Therefore, it is of great significance to find drugs for the treatment of bladder cancer.

Deoxyschizandrin schizandrin is a lignan compound in the extract of dried and mature fruit of Schisandra chinensis (Turcz.) Baill, which is a Magnoliaceae plant. Deoxyschizandrin is one of the effective components of Schisandra chinensis [3]. It has vasodilating, immunosuppressive, anti-inflammatory, and antiviral activities [4].

A large number of experiments have also verified that Deoxyschizandrin plays a significant role in the process of antitumor treatment. It can not only significantly inhibit
the growth and induce apoptosis of a variety of tumor cells but also inhibit EMT and tumor angiogenesis of various tumors through a variety of signal pathways, so as to inhibit tumor invasion and metastasis, such as breast cancer and thyroid cancer, glioma, pancreatic cancer, liver cancer, and ovarian cancer [5–11]. However, the effect of Deoxyschizandrin on bladder cancer cells and its mechanism are still unclear. So the effects of Deoxyschizandrin on the proliferation, migration, invasion, and apoptosis of bladder cancer cells were investigated, so as to provide a new theoretical and experimental basis for the application of schisandrin A in the clinical treatment of bladder cancer.

ALOX5 (arachidonic acid 5-lipoxygenase) is a key enzyme in arachidonic acid metabolism. ALOX5 gene is located on chromosome 10q11.2, with a length of 7 188 kb. The expression is low in the physiological state, upregulated in pathological situations, and is related to the occurrence and development of the disease. It is related to the prognosis and progression of tumors [12–15], which plays an important role in malignant biological behavior of cancer cells. In a variety of solid tumors, the abnormal expression or overexpression of ALOX5 is related to tumor cell proliferation, differentiation, invasion, metastasis, inhibition of apoptosis, and so on. ALOX5 was found to promote tumorigenesis through the regulation of p53 [16–19].

In this experiment, we found that Deoxyschizandrin can inhibit proliferation, invasion, metastasis, and clone formation in vitro and promote apoptosis in bladder cancer cells. Further, we also revealed the molecular mechanism of Deoxyschizandrin in bladder cancer cells, which laid a theoretical foundation for the application of Deoxyschizandrin in bladder cancer.

2. Materials and Methods

2.1. Cell Culture. HT1376 and J82 cells were purchased from the Cell Collection Committee of the Chinese Academy of Sciences (Shanghai, China). HT1376 and J82 cells were cultured in RPMI-1640 medium (Gibco, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA) at 37°C, 5% CO₂. When the degree of cell fusion is 75%-80%, the cells were digested and passaged with 0.25% trypsin solution. The logarithmic growth phase cells in good condition were selected for subsequent experiments.

2.2. Cell Transfection. The cell density was adjusted to 1 × 10⁵ cells/mL. Then, 2 mL cell suspension was added and inoculated into 6-well plate and cultured at 37°C, 5% CO₂ for 48 h. Subsequently, the ALOX5 overexpression vector was transfected into HT1376 and J82 cells. The transfection method was referred to the instructions of Lipofectamine 3000 transfection reagent (Invitrogen, USA). After 48 hours of transfection, total RNA and protein were extracted from HT1376 and J82 cells, and the expression of ALOX5 mRNA and protein was detected by RT-PCR and Western blot, respectively.

2.3. CCK-8 Assay. The cell density was adjusted to 2 × 10⁴ cells/mL. Then, 0.1 mL cell suspension was added and inoculated into 96-well plate and cultured at 37°C, 5% CO₂ for 12 h. The cells were treated with 0.5, 5, 10, 50, and 100 μmol/L Deoxyschizandrin (Med Chem Express, USA), and the control group was added with equal volume PBS for 24 h, 48 h, and 72 h, respectively. Then, 10 μL CCK-8 reagent (Dojindo, Japan) was added and incubated for 2 h. The absorbance was detected by the BioTek (Winooski, USA) microplate spectrophotometer at 450 nm and repeat 3 times for each group.

2.4. RNA Isolation and Real-Time PCR. Total RNA was extracted by TRIzol reagent (Invitrogen, CA, USA) and reverse transcribed into cDNA by the TaKaRa system (Takara, Dalian, China). According to the instructions of RT-PCR kit (Thermo Fisher, USA), the relative expression was calculated by formula 2⁻ΔCT.

2.5. Wound Healing. The cell density was adjusted to 5 × 10⁵ cells/mL. Then, 1 mL cell suspension was added and inoculated into 6-well plate and cultured at 37°C, 5% CO₂ for 48 h. The cells are covered with 6-well plates, using a 200 μL pipette tip to make a “...” one scratch along the bottom. After 0.5, 5, and 10 μmol/L Deoxyschizandrin treatment of the cells for 24 h, the scratch separation was observed, measured, and photographed, and the cell migration inhibition rate was calculated.

2.6. Transwell Assay. The cell density was adjusted to 1 × 10⁵ cells/mL by serum free medium. Then, 0.1 mL cell suspension was added and inoculated onto the upper chambers and the lower chambers and was added 0.5 mL containing 10% FBS medium. After 0.5, 5, and 10 μmol/L Deoxyschizandrin treatment of the cells for 48 h, the culture medium was discarded, and the upper chambers were washed with PBS for three times, then fixed with 4% paraformaldehyde solution, and stained with crystal violet for 15 min. The number of invasive cells was calculated by light microscope (Nikon, Japan).

2.7. In Vitro Tumor Xenografts. The cell density was adjusted to 1 × 10⁷ cells/mL by serum free medium. Then, 0.2 mL cell suspension was added into the upper back of nude mice. Subsequently, 25 mg/kg Deoxyschizandrin or PBS was injected into nude mice. The tumor volume of nude mice was measured every 7 days for 4 weeks, and the tumor volume was calculated by formula 1/2 × L × W². This study had been approved by the Committee on the Ethics of Animal Experiments of the First Affiliated Hospital of Jiamusi University. The ethics committee approval number of our study is 2018031.

2.8. Bioinformatics Prediction of Protein Targets of Deoxyschizandrin. The three-dimensional structure file of Deoxyschizandrin was downloaded from the PubChem compound database (https://www.ncbi.nlm.nih.gov/ pccompound); then, we uploaded the structure file of Deoxyschizandrin into SwissTargetPrediction database (http:// www.swisstargetprediction.ch/) to obtain the protein target of Deoxyschizandrin.
2.9. Western Blot Assay. The cell density was adjusted to $1 \times 10^6$ cells/mL. Then, 1 mL cell suspension was added and inoculated into 6-well plate and cultured at 37°C, 5% CO$_2$ for 24 h. The cells were treated with 5, 10, and 50 μmol/L Deoxyschizandrin, and the control group was added with equal volume PBS for 24 h. The cells were lysed with RIPA reagent containing 1% PMSF and centrifuged 12 000 r/min at 4°C for 15 min. The protein concentration was quantified by BCA assay (Thermo Scientific, USA). Then, 30 μg protein samples were loaded, electrophoretic, transferred, and blocked. The primary antibodies (1 : 1 000) were added and incubated overnight at 4°C and washed by TBST three times. The corresponding secondary antibodies were added and incubated at room temperature for 120 min and washed by TBST three times. The exposure solution was added dropwise in a dark room for exposure development, and the protein target band was analyzed with ImageJ software. The experiment was repeated three times.

2.10. Statistical Analysis. Statistical analysis was performed using GraphPad Prism 6.0 statistical software. Cell proliferation rate, cell migration, cell invasion, tumor formation in vitro, RT-PCR, cell apoptosis rate, and other measurement data are shown as $\bar{x} \pm s$, and $t$ test is used for comparison between two groups. $p < 0.05$ was considered statistically significant.

3. Results

3.1. Deoxyschizandrin Inhibits the Proliferation of Bladder Cancer Cell Line. At first, two kinds of bladder cancer cells were treated with different concentration gradients of Deoxyschizandrin (0.5, 5, 10, 50, and 100 μmol/L) and different time (24 h, 48 h, and 72 h). Then, CCK-8 assay was used to analyze the growth and proliferation of the two kinds of cells (HT1376 and J82). At 24 h, 48 h, and 72 h, Deoxyschizandrin had a significant inhibitory effect on the growth of bladder cancer cells (HT1376 and J82), which increased with the increase of concentration in a dose-dependent manner (Figures 1(a)–1(f)).

3.2. Deoxyschizandrin Inhibits the Migration, Invasion, and In Vitro Tumorigenesis of Bladder Cancer Cell Lines. In order to study the effect of Deoxyschizandrin on the migration ability of bladder cancer cells, according to the above experimental results, 0.5, 5, and 10 μmol/L Deoxyschizandrin were used to treat bladder cancer cells. After 48 hours, the migration and invasion ability of bladder cancer cells (HT1376 and J82) were significantly reduced, which was significantly lower than that of the control group (Figures 2(a)–2(h)). WB revealed that E-cadherin was decreased after Deoxyschizandrin treatment (Figures 2(i) and 2(j)). Similar results were obtained in vitro tumorigenesis (Figures 2(k) and 2(l)).
**Figure 2: Continued.**

(a) Wound healing rate (%) for HT1376 cells treated with different concentrations of Deoxyschizandrin.

(b) Wound healing rate (%) for J82 cells treated with different concentrations of Deoxyschizandrin.

(c) Wound healing rate (%) for J82 cells treated with different concentrations of Deoxyschizandrin.

(d) Wound healing rate (%) for J82 cells treated with different concentrations of Deoxyschizandrin.

(e) Number of invasive cells for HT1376 cells treated with different concentrations of Deoxyschizandrin.

(f) Number of invasive cells for HT1376 cells treated with different concentrations of Deoxyschizandrin.

(g) Number of invasive cells for J82 cells treated with different concentrations of Deoxyschizandrin.

(h) Number of invasive cells for J82 cells treated with different concentrations of Deoxyschizandrin.

(i) Western blot analysis of E-cadherin, Vimentin, and GAPDH for HT1376 cells treated with different concentrations of Deoxyschizandrin.

(j) Western blot analysis of E-cadherin, Vimentin, and GAPDH for J82 cells treated with different concentrations of Deoxyschizandrin.
Deoxyschizandrin and overexpression of ALOX5 group PI3K and p-AKT protein was recovered after treatment with Deoxyschizandrin, while the expression of p-AKT protein compared with the control group. The expression of p-PI3K and p-AKT protein was decreased with the concentration of Deoxyschizandrin.

After 48 hours, the expressions of ALOX5 mRNA and protein were decreased with the concentration of Deoxyschizandrin (Figures 3(b)–3(d)). It was found that the protein target with the highest degree score was ALOX5. In order to study whether Deoxyschizandrin can regulate the expression of ALOX5, bladder cancer cells were treated with 5, 10, and 50 μmol/L Deoxyschizandrin. After 48 hours, the expressions of ALOX5 mRNA and protein were decreased with the concentration of Deoxyschizandrin (Figures 3(b)–3(d)).

3.3. Bioinformatics Prediction of Protein Targets of Deoxyschizandrin. Using the online database PubChem (https://pubchem.ncbi.nlm.nih.gov/) to download the chemical structure of Deoxyschizandrin (Figure 3(a)) and then using the online database SwissTargetPrediction (http://www.swistargetprediction.ch/index.php), we predicted that there were 100 protein targets of Deoxyschizandrin. It was found that the protein target with the highest degree score was ALOX5. Therefore, it is very important to study whether Deoxyschizandrin can inhibit the proliferation, migration, and invasion of bladder cancer cells by ALOX5 and regulating the downstream PI3K-Akt signaling pathway.

3.4. Deoxyschizandrin Inhibits the Proliferation, Migration, and Invasion of Bladder Cancer Cells by Downregulating ALOX5 and Affecting the Downstream PI3K-Akt Signaling Pathway. The results of CCK-8, wound healing, and Transwell assay showed that compared with the control group, the proliferation, migration, and invasion ability of bladder cancer cells were enhanced after overexpression of ALOX5, while the proliferation, migration, and invasion ability of bladder cancer cells were decreased after overexpression of ALOX with Deoxyschizandrin (Figures 4(a)–4(j)). Similar results were obtained in vitro tumorigenesis and Ki-67 (Figures 4(k)–4(m)). HE results the toxicity of the liver and kidney, and Deoxyschizandrin displayed no obvious cytotoxicity in mice (Figure 4(n)). Western blot results showed that overexpression of ALOX5 could increase the expression of p-PI3K and p-AKT protein with the control group. The expression of p-PI3K and p-AKT protein was recovered after treatment with Deoxyschizandrin and overexpression of ALOX5 group (Figures 4(o) and 4(p)). These results indicated that Deoxyschizandrin can inhibit the proliferation, migration, and invasion of bladder cancer cells by ALOX5 and regulating the downstream PI3K-Akt signaling pathway.

4. Discussion

Bladder cancer is a common tumor of the urinary system. Incidence rate and mortality rate have been increasing year by year. 10%-30% of bladder cancer will progress to muscle invasive bladder cancer with high invasion, rapid progression, and metastasis, and the prognosis is often poor [20–24]. Therefore, it is very important to study the antitumor drugs for bladder cancer. Chemotherapy is an important part of the treatment plan, especially after bladder cancer surgery. At present, more and more drug resistance is produced in the occurrence and development of tumor, which brings new challenges to the treatment [25–27]. Therefore, it is an important strategy to find new drugs or treatment methods and reduce the distant metastasis of bladder cancer.

In recent years, the potential value of Chinese medicine extracts in China has increased. More and more attention has been paid to the value of traditional Chinese medicine extracts in the treatment of bladder cancer. Currently, a variety of traditional Chinese medicines and their active ingredients have demonstrated good activity against bladder cancer. Schisandra chinensis has reported antitumor effect, and its antitumor effect is mainly concentrated in lignans and polysaccharides. Deoxyschizandrin is one of the main components of lignans.

In recent years, more and more studies have shown that schisandrin A has significant and extensive antitumor activity, and the research on its molecular mechanism has gradually deepened. Schisandrin A can effectively inhibit tumor cell proliferation, induce tumor cell apoptosis, reverse tumor...
cell chemoresistance, inhibit tumor cell invasion and metastasis, and cooperate with anticancer drugs to enhance efficacy and chemosensitivity. The results showed that different concentrations of Deoxyschizandrin could significantly inhibit the growth, migration, invasion, and in vitro tumorigenesis and promote apoptosis of bladder cancer cells in a concentration dependent manner. It is suggested that Deoxyschizandrin has potential medicinal value in the treatment of bladder cancer. At present, the antitumor research of SCH A is mainly focused on the cell level. Most of the research on the synergistic effect produced by the combination of Deoxyschizandrin and various chemotherapeutic drugs are limited to cell experiments and a small number of animal experiments. There are few related clinical trials. More research is still needed to prove the effect of Deoxyschizandrin’s antitumor effect in human body.

PI3K/AKT signaling pathway, as an oncogene signaling pathway, plays an important role in cell growth, proliferation, survival, transcription, and protein synthesis [28–32]. In our study, Deoxyschizandrin inhibits PI3K/AKT signaling pathway through ALOX5, which is closely related to inhibiting cell proliferation and promoting apoptosis. Western blot analysis showed that Deoxyschizandrin could inhibit the expression of p-PI3K and p-AKT.

**Figure 3:** Deoxyschizandrin can regulate the expression of ALOX5 in BC cell. (a) The chemical structure of Deoxyschizandrin. (b) qRT-PCR analysis of mRNA expression levels of ALOX5 in HT1376 and J82 cells treated with Deoxyschizandrin or negative control. (c and d) Western blot analysis of protein expression levels of ALOX5 in HT1376 and J82 cells treated with Deoxyschizandrin or negative control. Data represent mean ± SD. *p < 0.05 compared with negative control.
Figure 4: Continued.
5. Conclusion

The results show that Deoxyschizandrin can inhibit the proliferation and migration of bladder cancer cells in vivo and in vitro and promote cell apoptosis through PI3K/AKT signaling pathway by ALOX5, indicating that Deoxyschizandrin may be used in the treatment of bladder cancer, but more cell line application studies and clinical studies are needed to verify it.

Data Availability

The data used to support the findings of this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare that they have no competing interests.
Authors’ Contributions
Baojin Chi and Yao Sun contributed equally to this work.

Acknowledgments
This work was supported by the Health and Family Planning Commission of Heilongjiang Province, China (Grant No. 2018-368), and President’s Innovative and Entrepreneurial Foundation of Jiamusi University (Grant No. RWSK2017-31).

References
[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] R. T. Bryan, “Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions,” Cancer, vol. 125, no. 4, pp. 652-653, 2019.
[3] A. Szopa, W. Kisiel, H. Ekiert, and A. Szweczyk, “Isolation of three dibenzocyclooctadiene lignans from in vitro cultures of Schisandra chinensis (Turcz.) Baill.–the first report,” Pharmazie, vol. 70, no. 5, pp. 337–339, 2015.
[4] S. Zhong, Y. C. Nie, Z. Y. Gan et al., “Effects of Schisandra chinensis extracts on cough and pulmonary inflammation in a cough hypersensitivity guinea pig model induced by cigarette smoke exposure,” Journal of Ethnopharmacology, vol. 165, pp. 73–82, 2015.
[5] X. Xu, V. Rajamanicham, S. Xu et al., “Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway,” Biomedicine & Pharmacotherapy, vol. 115, p. 108922, 2019.
[6] H. Yan and M. Guo, “Schisandrin A inhibits cellular phenotypes of breast cancer cells by repressing miR-155,” IUBMB Life, vol. 72, no. 8, pp. 1640–1648, 2020.
[7] Q. Ding, X. Li, Y. Sun, and X. Zhang, “Schisandrin A inhibits proliferation, migration and invasion of thyroid cancer cell line FTC-133 by down regulation of microRNA-429,” Cancer Biomarkers, vol. 24, no. 4, pp. 497–508, 2019.
[8] K. Lee, J. H. Ahn, K. T. Lee, D. Jang, and J. H. Choi, “Deoxy-schisandrin, isolated from Schisandra berries, induces cell cycle arrest in ovarian cancer cells and inhibits the protumoural activation of tumour-associated macrophages,” Nutrients, vol. 10, no. 1, p. 91, 2018.
[9] D. Kong, D. Zhang, X. Chu, and J. Wang, “Retracted: Schisan-drin A enhances chemosensitivity of colon carcinoma cells to 5-fluouracil through up-regulation of miR-195,” Biomedicine & Pharmacotherapy, vol. 99, pp. 176–183, 2018.
[10] H. Xian, W. Feng, and J. Zhang, “Schisandrin A enhances the efficacy of gefitinib by suppressing IKKβ/ERK signaling in non-small cell lung cancer,” European Journal of Pharmacology, vol. 855, pp. 10–19, 2019.
[11] B. C. Chen, S. L. Tu, B. A. Zheng, Q. J. Dong, Z. A. Wan, and Q. Q. Dai, “Schisandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1,” BioScience Reports, vol. 40, no. 3, 2020.
[12] D. Wang, Y. Li, C. Zhang, X. Li, and J. Yu, “MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting of COX-2 and ALOX5,” Journal of Cellular Biochemistry, vol. 119, no. 2, pp. 1755–1766, 2018.
[13] Z. Chen, X. Chen, H. Yan et al., “The lipoxigenase gene family in poplar: identification, classification, and expression in response to MelA treatment,” PLoS One, vol. 10, no. 4, p. e125526, 2015.
[14] X. Zhou, Y. Jiang, Q. Li, Z. Huang, H. Yang, and C. Wei, “Aberrant ALOX5 activation correlates with HER2 status and mediates breast cancer biological activities through multiple mechanisms,” BioMed Research International, vol. 2020, Article ID 1703531, 8 pages, 2020.
[15] T. Hayashi, K. Nishiyama, and T. Shirahama, “Inhibition of 5-lipoxigenase pathway suppresses the growth of bladder cancer cells,” International Journal of Urology, vol. 13, no. 8, pp. 1086–1091, 2006.
[16] B. Wang, S. C. Yu, J. Y. Jiang et al., “An inhibitor of arachidonate 5-lipoxigenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells,” Stem Cell Reviews and Reports, vol. 7, no. 2, pp. 458–470, 2011.
[17] A. Selka, J. A. Doiron, P. Lyons et al., “Discovery of a novel 2,5-dihydroxyaromatic acid-based 5-lipoxigenase inhibitor that induces apoptosis and may impair autophagic flux in RCCa renal cancer cells,” European Journal of Medicinal Chemistry, vol. 179, pp. 347–357, 2019.
[18] J. Chang, N. Tang, Q. Fang et al., “Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway,” Biochemical and Biophysical Research Communications, vol. 517, no. 1, pp. 1–7, 2019.
[19] J. Monga, D. Subramani, A. Bharathan, and J. Ghosh, “Pharmacological and genetic targeting of 5-lipoxigenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis,” Scientific Reports, vol. 10, no. 1, p. 6649, 2020.
[20] C. Pang, Y. Guan, H. Li, W. Chen, and G. Zhu, “Urologic cancer in China,” Japanese Journal of Clinical Oncology, vol. 46, no. 6, pp. 497–501, 2016.
[21] S. A. Boorjijian, M. Alemozaffar, B. R. Konyet et al., “Intravesical naldofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial,” The Lancet Oncology, vol. 22, no. 1, pp. 107–117, 2021.
[22] X. G. Zhang, T. Zhang, C. Y. Li, M. H. Zhang, and F. M. Chen, “CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer,” Cancer Medicine, vol. 7, no. 8, pp. 3763–3772, 2018.
[23] S. Shi and B. Tian, “Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis,” Cancer Biomarkers, vol. 24, no. 2, pp. 183–193, 2019.
[24] P. R. Campanario and P. F. Campanario, “Current treatment options and future perspectives on first line metastatic bladder cancer,” Archivos Españoles de Urología, vol. 73, no. 10, pp. 996–1006, 2020.
[25] Q. Meng, T. Lei, M. Zhang, J. Zhao, X. H. Zhao, and M. Zhang, “Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 3, pp. 509–519, 2013.
[26] J. A. Higgins, M. Zainol, K. Brown, and G. D. D. Jones, “Anthocyanins as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C,” Mutagenesis, vol. 29, no. 4, pp. 227–235, 2014.
[27] T. Nakayama, N. Nozawa, C. Kawada et al., “Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer,” *Photodiagnosis and Photodynamic Therapy*, vol. 31, p. 101893, 2020.

[28] C. Xie, M. Zhou, J. Lin et al., “EEF1D promotes glioma proliferation, migration, and invasion through EMT and PI3K/Akt pathway,” *BioMed Research International*, vol. 2020, Article ID 7804706, 12 pages, 2020.

[29] C. Shi, Y. Y. Wu, and L. Q. Wei, “MiR-221 affects the proliferation and apoptosis of laryngeal cancer cells through the PI3K/AKT signaling pathway,” *European Review for Medical and Pharmacological Sciences*, vol. 24, no. 3, pp. 1258–1263, 2020.

[30] J. Meng, G. J. Liu, J. Y. Song et al., “Preliminary results indicate resveratrol affects proliferation and apoptosis of leukemia cells by regulating PTEN/PI3K/AKT pathway,” *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 10, pp. 4285–4292, 2019.

[31] K. Zhou, J. Chen, J. Wu et al., “Profilin 2 promotes proliferation and metastasis of head and neck cancer cells by regulating PI3K/AKT/β-catenin signaling pathway,” *Oncology Research*, vol. 27, no. 9, pp. 1079–1088, 2019.

[32] P. Hao, B. Kang, Y. Li, W. Hao, and F. Ma, “UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma,” *Molecular Medicine Reports*, vol. 20, no. 2, pp. 1212–1220, 2019.